What tests confirm cystic fibrosis after newborn screening? 

In the United Kingdom, the newborn blood spot test often referred to as the heel prick test is a highly effective screening tool, but it is not a final diagnosis. If the screening result indicates a high level of immunoreactive trypsinogen (IRT), further confirmatory tests are required to determine if the baby has cystic fibrosis. These tests move beyond screening to look for physical and genetic evidence of the condition. The two primary methods used for confirmation are the sweat test, which measures salt levels on the skin, and detailed genetic analysis to identify specific mutations. These tests provide the clinical certainty needed for the specialist multidisciplinary team to begin a tailored treatment plan. 

What We’ll Discuss in This Article 

• The transition from newborn screening to confirmatory testing. 

• How the sweat test serves as the gold standard for diagnosis. 

• The role of genetic mutation analysis in confirming the condition. 

• Testing for pancreatic function using faecal elastase. 

• What happens during a diagnostic appointment at a specialist centre. 

• Understanding “borderline” results and the need for repeat testing. 

The confirmatory sweat test 

The sweat test is the most important and widely used test for confirming a diagnosis of cystic fibrosis in both infants and adults. According to the NHS, people with cystic fibrosis have a higher level of salt in their sweat than people who do not have the condition. This occurs because the faulty CFTR protein in the sweat glands cannot reabsorb chloride effectively. The test is safe, non-invasive, and can usually be performed as soon as a baby is two weeks old, provided they are large enough to produce a sufficient amount of sweat. 

During the procedure, a healthcare professional applies a sweat-inducing chemical to a small area of skin on the arm or leg. A very weak electrical current is used to stimulate the sweat glands, after which the sweat is collected over 30 minutes using a special plastic coil or filter paper. The collected sweat is then sent to a laboratory to measure the concentration of chloride. NICE guidance specifies that a chloride level of 60 mmol/L or above is diagnostic of cystic fibrosis. If the result is between 30 and 59 mmol/L, it is considered borderline and usually warrants further genetic investigation or a repeat sweat test. 

Detailed genetic mutation analysis 

While the initial newborn screening may check for a few common genetic faults, confirmatory genetic testing involves a more comprehensive look at the baby’s DNA. This is done to identify the two specific mutations (one from each parent) that cause the condition. Identification of these mutations is now a vital part of modern care because it determines eligibility for the latest modulator medications. In the UK, laboratories typically use a panel that covers the 30 to 50 most common mutations found in the British population, including the Delta F508 mutation. 

If a sweat test is positive but the standard genetic panel only finds one or no mutations, the specialist team may request “extended gene sequencing.” This process involves looking at the entire length of the CFTR gene to find rarer mutations. The Cystic Fibrosis Trust notes that finding both mutations confirms the diagnosis and helps doctors predict how the condition might affect the child’s respiratory and digestive health. 

Assessing pancreatic function 

Once a diagnosis is confirmed via sweat or genetic testing, the clinical team will assess how the condition is affecting the baby’s digestive system. This is primarily done through a faecal elastase test. This test requires a small stool sample to measure the level of elastase, an enzyme produced by the pancreas. If the elastase level is low, it indicates “pancreatic insufficiency,” meaning the pancreas is blocked by mucus and is not releasing enough enzymes to digest food. This result confirms that the baby will need to start taking Pancreatic Enzyme Replacement Therapy (PERT) with their feeds to ensure they grow and gain weight appropriately. 

Understanding inconclusive or borderline results 

In some cases, the combination of a sweat test and genetic testing does not provide a clear “yes” or “no” answer. This situation is referred to as Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID). This may happen if a child has a borderline sweat test result and only one mutation that is clearly known to cause cystic fibrosis, or two mutations that are known to cause very mild symptoms. 

Children with CFSPID are usually monitored by a specialist centre rather than being treated immediately for cystic fibrosis. The NHS monitors these children to see if they develop any clinical signs of the condition as they grow, such as a persistent cough or poor weight gain. In many cases, these children remain healthy, but the monitoring ensures that if the condition does begin to manifest, treatment can start without delay. 

Test Name	What it Measures	Significance
Sweat Test	Chloride (salt) concentration in sweat.	Gold standard for clinical diagnosis.
Genetic Analysis	Specific faults in the CFTR gene.	Confirms inheritance and guides treatment.
Faecal Elastase	Pancreatic enzyme levels in stool.	Determines the need for digestive enzymes.
IRT (Heel Prick)	Pancreatic protein in the blood.	Initial screening only; does not confirm CF.

Conclusion 

ConfirmiIs the sweat test painful for a baby? g a diagnosis of cystic fibrosis after a positive newborn screening result requires a combination of physical and genetic evidence. The sweat test remains the most reliable method for identifying the characteristic salt imbalance of the condition, while detailed genetic mapping identifies the specific mutations involved. Together with assessments of pancreatic function, these tests allow the specialist team to provide an accurate diagnosis and begin a comprehensive, lifelong care plan for the patient. 

If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article explains the clinical pathway for confirming cystic fibrosis in the UK, adhering strictly to the protocols set by the NHS and NICE. The content is developed by a professional medical writing team and has been reviewed by Dr. Rebecca Fernandez, a UK-trained physician with extensive experience in internal medicine, cardiology, and emergency care. This information is intended to help families understand the diagnostic process and the standard of care they can expect from specialist centres in the United Kingdom.